文献速递痛风与晶体性关节病

痛风患者在急性发作期、间歇期和达标治疗期的全身炎症细胞因子谱:TNFSF14作为新生物标志物

Systemic inflammatory cytokine profiles in patients with gout during flare, intercritical and treat-to-target phases: TNFSF14 as new biomarker.
PubMed 文献 · Ann Rheum Dis · 2024-06-12

本研究采用Olink靶向蛋白质组学在痛风患者急性发作期(T1)、间歇期(T2)和降尿酸达标后(T3)检测92种炎症相关蛋白,并在独立队列中验证。结果发现21种新炎症生物标志物在三个时间点差异表达,其中IL-6和TNFSF14在T1较T2或T3表达倍数变化最高;TNFSF14在炎症关节产生并增强脂多糖和尿酸盐结晶诱导的炎症反应,而阻断TNFSF14可减轻炎症反应。

要点

  • 21种炎症生物标志物在痛风三个时点差异表达,IL-6和TNFSF14在发作期表达倍数变化最高。
  • TNFSF14在炎症关节产生,增强脂多糖和尿酸盐结晶诱导的炎症反应,阻断后可减轻炎症反应。
  • TNFSF14的单核苷酸多态性影响髓系细胞产生炎症细胞因子的能力。

核心结论

  • 痛风急性发作涉及多种炎症介质,这些介质可能作为潜在治疗靶点。

研究设计与样本

  • 使用Olink靶向蛋白质组学检测前瞻性痛风队列(GOUTROS)在痛风发作期(T1)、间歇期(T2)和降尿酸治疗达标后(T3)血浆中92种炎症相关蛋白水平。
  • 在独立队列(OLT1177-05)中验证T1和T2采集的血浆结果,并进行离体和体外实验评估新生物标志物的炎症特性。

主要发现

  • 共有21种新炎症生物标志物在痛风三个时间点差异表达。
  • 在独立队列中,四种蛋白(白介素6(IL-6)、集落刺激因子1、血管内皮生长因子A和肿瘤坏死因子超家族成员14(TNFSF14))在痛风发作期水平升高。
  • IL-6和TNFSF14在T1较T2或T3表达倍数变化最高。
  • TNFSF14在炎症关节产生,并增强脂多糖和尿酸盐结晶刺激诱导的炎症反应;反之,阻断TNFSF14可减轻炎症反应。
  • TNFSF14的单核苷酸多态性影响髓系细胞产生炎症细胞因子的能力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Untreated gout is characterised by monosodium urate (MSU) crystal accumulation responsible for recurrent flares that are commonly separated by asymptomatic phases. Both phases are inflammatory conditions of variable intensity. Gout flares are self-limited inflammatory reactions involving multiple mediators. This study aimed to characterise the inflammatory profiles of gout at different phases. METHODS: Using the Olink targeted proteomics, levels of 92 inflammation-related proteins were measured in plasma samples of a prospective gout population (GOUTROS), collected at gout flare (T1), the intercritical phase (T2) and after reaching the target serum urate level under urate-lowering therapy (T3). Results were validated in an independent cohort (OLT1177-05) with plasmas collected at T1 and T2. Ex vivo and in vitro experiments were performed to assess the inflammatory properties of new biomarkers. RESULTS: In total, 21 inflammatory new biomarkers were differentially expressed during the three time-points of gout disease. The levels of four of these proteins (interleukin 6 (IL-6), colony-stimulating factor 1, vascular endothelial growth factor A and tumour necrosis factor superfamily 14 (TNFSF14)) were increased during gout flare in an independent cohort. IL-6 and TNFSF14 had the highest fold change in expression during T1 versus T2 or T3. TNFSF14 was produced at the inflamed joint and enhanced the inflammatory response induced by lipopolysaccharide and MSU crystal stimulation. Conversely, TNFSF14 blockade reduced the inflammatory response. Additionally, single nucleotide polymorphisms of TNFSF14 affected the ability of myeloid cells to produce inflammatory cytokines. CONCLUSION: Gout flare involves multiple inflammatory mediators that may be used as potential therapeutic targets.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Ea HK, Kischkel B, Chirayath TW, et al. Systemic inflammatory cytokine profiles in patients with gout during flare, intercritical and treat-to-target phases: TNFSF14 as new biomarker. Ann Rheum Dis. 2024. PMID: 38373842. doi:10.1136/ard-2023-225305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。